Epilepsy
51 programs · 49 companies
Programs
51
Companies
49
Trials
44
MOAs
32
BCL-2iTNFiCD47iHER2IL-13iWRNiPARPiC5iMDM2iHPK1i
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Phase 1 | BTK | ||
| AZN-7403 | Phase 2/3 | FGFR | ||
| AZN-6294 | Phase 2/3 | APOC3 | ||
| Datobrutinib | Phase 3 | Aβ | ||
| AMG-1919 | Phase 2/3 | CDK2 | ||
| REG-7737 | Preclinical | CD123 | ||
| BNT-5232 | NDA/BLA | TIGIT | ||
| Rimabrutinib | Phase 1/2 | GPRC5D | ||
| VKT-4052 | Phase 2/3 | TNFα | ||
| Elralucimab | Phase 2 | CDK4/6 | ||
| CRS-6525 | Phase 2 | CD20 | ||
| Semamavacamten | Phase 1/2 | AuroraA | ||
| RCU-8819 | Preclinical | B7-H3 | ||
| BEA-2615 | Phase 3 | PRMT5 | ||
| Polazumab | Phase 2/3 | IL-13 | ||
| Lisoinavolisib | Approved | TIGIT | ||
| Motacapivasertib | NDA/BLA | MDM2 | ||
| Riboglumide | Phase 2 | MALT1 | ||
| EYE-3796 | Phase 3 | CFTR | ||
| CRN-1592 | Phase 1/2 | CD20 | ||
| APM-3452 | Phase 1/2 | CD19 | ||
| NOR-5927 | Phase 1 | CGRP | ||
| Ivofotisoran | NDA/BLA | CD38 | ||
| KAR-5490 | Phase 1 | RET | ||
| INT-430 | Phase 2/3 | CD19 | ||
| Riluzasiran | Phase 2/3 | SHP2 | ||
| Peminesiran | Phase 1 | TIGIT | ||
| 456-7078 | Phase 1/2 | TIM-3 | ||
| Talazumab | Phase 2/3 | B7-H3 | ||
| Ivolemzoparlimab | Approved | DLL3 | ||
| IMV-3202 | Approved | Tau | ||
| Motamavacamten | Preclinical | JAK1 | ||
| Ribosotorasib | Approved | HER2 | ||
| Gozesertib | Phase 1/2 | CDK2 | ||
| Geliglumide | Phase 2/3 | TIM-3 | ||
| TXM-5550 | NDA/BLA | KRASG12C | ||
| FER-2526 | NDA/BLA | CD47 | ||
| Gelicapivasertib | Approved | Aβ | ||
| Olpaglumide | Approved | KRASG12C | ||
| Mirisacituzumab | NDA/BLA | SOS1 | ||
| BPT-5103 | Phase 2 | PSMA | ||
| Ivozasiran | Phase 1/2 | Tau | ||
| JUB-6215 | Phase 2/3 | CD20 | ||
| VIN-1694 | Approved | AuroraA | ||
| Polabrutinib | Preclinical | FcRn | ||
| NEO-1964 | Phase 3 | IL-13 | ||
| Ribozasiran | Phase 1/2 | C5 | ||
| Pemicagene | Approved | IL-13 | ||
| 002-8467 | Phase 1/2 | SHP2 | ||
| Bemaratamab | Phase 2/3 | CFTR | ||
| Fixatuximab | Phase 3 | JAK1 |
Trials (44)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT05881920 | PFE-5501 | Phase 1 | Active |
| NCT04338344 | AZN-6294 | Phase 2/3 | Active |
| NCT06911553 | Datobrutinib | Phase 3 | Recruiting |
| NCT07881271 | REG-7737 | Preclinical | Terminated |
| NCT06092455 | REG-7737 | Preclinical | Terminated |
| NCT05334731 | BNT-5232 | NDA/BLA | Not yet recr... |
| NCT07840002 | Rimabrutinib | Phase 1/2 | Terminated |
| NCT07481208 | Rimabrutinib | Phase 1/2 | Recruiting |
| NCT07116897 | VKT-4052 | Phase 2/3 | Terminated |
| NCT07727959 | VKT-4052 | Phase 2/3 | Terminated |
| NCT04708901 | Elralucimab | Phase 2 | Completed |
| NCT04580950 | Semamavacamten | Phase 1/2 | Not yet recr... |
| NCT06413381 | RCU-8819 | Preclinical | Recruiting |
| NCT03109304 | BEA-2615 | Phase 3 | Active |
| NCT05413928 | Lisoinavolisib | Approved | Active |
| NCT04967339 | Motacapivasertib | NDA/BLA | Active |
| NCT04982046 | Riboglumide | Phase 2 | Terminated |
| NCT07243471 | NOR-5927 | Phase 1 | Recruiting |
| NCT07077631 | NOR-5927 | Phase 1 | Recruiting |
| NCT03891122 | Ivofotisoran | NDA/BLA | Terminated |